Democratizing Access, Speed, and Cost for Clinical Trials in Kazakhstan

50%+ cost reduction. 5 months to SSU. Powered by Tigermed, the #1 CRO in Asia.

Start Feasibility Assessment
0+ Clinical Trials Conducted
0M+ Patient Health Records
0%+ Average Cost Savings
0+ JCI-Accredited Hospitals
Scroll to explore
The Problem

The Science Works, The Math Doesn't

Capital concentration and escalating investor expectations prevent startups from funding the clinical trials needed to reach approval.

The Funding Gap

Capital Requirements

$2B median FDA-approved drug cost, $30M is all most startups will ever raise.

Capital Concentration

Market Structure

82% of biotech capital held by just 11 mega-funds.

Mega-Rounds Dominate

Trend Analysis

90%+ of startups never raise enough to finish a clinical trial.

Where Capital Flows

Phase Distribution

86% of capital goes to late-stage trials, starving Preclinical & Phase I.

The Solution

Kazakhstan is The Game Changer

FDA-Aligned by Design

Protocols built on FDA compliance and protocol

2-3x Faster Launch

Streamlined approvals, accelerated recruitment

70-80% Cost Savings

Nationalized hospitals, structurally lower costs

Full Sovereign Backing

Government-operated healthcare ecosystem

250+ completed & ongoing trials in Kazakhstan | Accepted by FDA, EMA, NMPA, MHRA
See It In Action

Big pharma trusts Kazakhstan.

With over 250 trials conducted to date, Kazakhstan is an emerging player on the global stage with a decade-long track record with big pharma

Operating across Central Asia
Government-backed partnership
FDA / EMA / ICH-GCP compliant
Astana Kazakhstan
Why Kazakhstan

The World's Best-Kept Secret in Clinical Research

Kazakhstan offers a unique convergence of government backing, world-class medical infrastructure, and a treatment-naive patient population.

Government Partnership

Strategic alliance with Kazakhstan's government ensures regulatory support, site access, and institutional backing.

10 JCI-Accredited Hospitals

World-class clinical infrastructure across the country with experienced investigators and modern facilities.

Accelerated Approvals

Streamlined regulatory framework enables faster trial approvals compared to traditional Western markets.

No Clinical Trial Saturation

Highly unlikely to have competing trials in the same indication — access untapped patient populations.

Astana skyline at sunset
Astana, Capital of Kazakhstan
Kazakhstan flag with Bayterek tower
Bayterek Tower, Astana
Exclusive Partnership

The #1 CRO in Asia.
Vantage + Tigermed

  • Top 10 CRO Globally and #1 in Asia
  • 11,000 Employees across 37 Countries
  • 3,200 clients and 3,500+ sites managed
  • 831 drug and 614 device trials ongoing
  • 700+ successful inspections by the FDA, EMA, NMPA, and MHRA
Strategic Partnership

Vantage + Tigermed

Combining Kazakhstan's clinical infrastructure with Asia's #1 CRO to deliver FDA/EMA/ICH-GCP compliant trials at unprecedented efficiency.

Vantage

Infrastructure, Government Integration, Sites

  • Government Backing and Integration
  • Kazakhstan Trial Management
  • Accelerated Patient Recruitment
  • Clinical Site Contracting
  • PI Selection
  • Local Regulatory Approvals

Tigermed

Execution, Monitoring, SOPs, Regulatory Compliance

  • Standard Operating Procedures
  • Monitor Training
  • Data Management
  • Analytics & Reporting
  • Sponsor Management
  • Lab Infrastructure
$1B+
Annual Revenue
10K+
Employees Worldwide
#1
CRO in Asia
30+
Years Combined Experience
Regulatory Compliance

FDA-Accepted Foreign Clinical Data

Clinical data from Kazakhstan is accepted by the FDA, EMA, and other major regulatory bodies worldwide.

TITLE 21. FOOD AND DRUGS

PART 314. APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG

Sec. 314.106 Foreign data.

An application based solely on foreign clinical data meeting U.S. criteria for marketing approval may be approved if:
  1. The foreign data are applicable to the U.S. population and U.S. medical practice;
  2. The studies have been performed by clinical investigators of recognized competence;
  3. The data may be considered valid without the need for an on-site inspection by FDA.
FDA FDA
EMA EMA
MHRA MHRA
JCI Accredited
ICH-GCP Compliant
FDA 21 CFR Part 11
Multi-National Ready
Get Started

Ready to Transform Your Clinical Program?

Start your feasibility assessment today and discover how Vantage can reduce your clinical trial costs by 50%+ while accelerating time to market.

Info@vantage-ct.com
NYC, USA
Dubai, UAE
Astana, Kazakhstan

Feasibility Assessment

  • FIH / POC
  • Phase 1
  • Phase 2
  • Phase 3
  • Oncology
  • Neurology
  • Metabolic
  • Cardiovascular
  • Other
  • 10 – 25
  • 25 – 50
  • 50 – 100
  • 100+
  • Today
  • Within 3 Months
  • Within 6 Months
  • Within a Year